FDA Approves Wearable Cardioverter Defibrillator
The patch-based cardioverter defibrillator is approved for use in patients with a temporary elevated risk of sudden cardiac arrest.
The patch-based cardioverter defibrillator is approved for use in patients with a temporary elevated risk of sudden cardiac arrest.
Philips’ cardiac telemetry Monitoring Service Application did not route some ECG events from July 2022 to July 2024 for cardiology review.
Restore Medical's ContraBand device received FDA Breakthrough Device Designation for treating heart failure with reduced ejection fraction.
The patch-based cardioverter defibrillator is approved for use in patients with a temporary elevated risk of sudden cardiac arrest.
Ultromics’ EchoGo Heart Failure, an AI solution for echocardiography to help diagnosis heart failure, received FDA clearance.
Read MoreA study published in Nature Medicine reports the ability of a smartwatch ECG to accurately detect heart failure in nonclinical environments.
Read MoreViz.ai will offer Us2.ai’s echocardiogram viewing and measurement tools with the Viz Platform to support those with suspected heart disease.
Read MoreCorVista Health was granted Breakthrough Device Designation for a non-invasive diagnostic solution for those with pulmonary hypertension.
Read MoreMedtronic received U.S. FDA approval for expanded labeling of a cardiac lead that taps into the heart’s natural electrical system.
Read MoreAccurKardia will collaborate with Mawi to integrate its proprietary ECG analytics into Mawi’s new cardiac monitoring watch.
Read MoreHeartBeam announced the expansion of its product portfolio pipeline to serve the growing cardiac device wearable technology market.